000472123 001__ 472123
000472123 005__ 20250724175817.0
000472123 020__ $$a978-1-0716-1011-4 (print)
000472123 020__ $$a978-1-0716-1012-1 (electronic)
000472123 0247_ $$2doi$$a10.1007/978-1-0716-1012-1_8
000472123 0247_ $$2ISSN$$a1064-3745
000472123 0247_ $$2ISSN$$a1940-6029
000472123 0247_ $$2altmetric$$aaltmetric:93323438
000472123 0247_ $$2pmid$$apmid:33108661
000472123 0247_ $$2openalex$$aopenalex:W3096208355
000472123 037__ $$aPUBDB-2021-04846
000472123 041__ $$aEnglish
000472123 1001_ $$0P:(DE-HGF)0$$aLucas, Alexandra R.$$b0$$eEditor
000472123 245__ $$aMethods for Crystallization and Structural Determination of M-T7 Protein from Myxoma Virus
000472123 260__ $$aNew York, NY$$bSpringer$$c2021
000472123 300__ $$a297
000472123 3367_ $$2BibTeX$$aBOOK
000472123 3367_ $$0PUB:(DE-HGF)3$$2PUB:(DE-HGF)$$aBook$$bbook$$mbook$$s1640611477_23238
000472123 3367_ $$2DataCite$$aOutput Types/Book
000472123 3367_ $$2ORCID$$aBOOK
000472123 3367_ $$01$$2EndNote$$aBook
000472123 3367_ $$2DRIVER$$abook
000472123 4900_ $$aMethods in Molecular Biology$$v2225
000472123 520__ $$aThe myxoma virus has become of interest in human medicine in the last two decades as it has the ability to infect many types of human cancer cells and is being used as a platform to develop viro-therapeutic agents that suppress aggressive and damaging immune responses and inflammation. Furthermore, the myxoma virus encodes proteins that have strong immunosuppressive effects, and several of the myxoma virus-encoded immunomodulators are being developed to treat systemic inflammatory syndromes such as cardiovascular disease and transplant rejection. Myxoma virus encodes the M-T7 protein, the most abundantly secreted protein expressed in myxoma virus-infected cells, originally identified as a rabbit species-specific interferon-gamma (IFN-γ) receptor homolog and as a chemokine-modulating protein binding a wide range of mammalian chemokines. M-T7 is a critical virulence factor for viral pathogenesis that increases virus lethality when expressed. Although M-T7 has been extensively studied using biochemical and biophysical techniques and its interactome map is well known, its three-dimensional (3D) structure remains elusive. Obtaining the 3D structure of M-T7 would be greatly beneficial and is a crucial step toward advancing M-T7 research through understanding the molecular function and activity of M-T7 as a novel therapeutic reagent and to rationally develop this protein as a drug. This chapter provides an overview of the structural determination techniques, especially X-ray crystallography, that can be applied toward the goal of achieving the first high-resolution structure of M-T7. In addition, details of up-and-coming methods are discussed, including X-ray diffraction at X-ray free electron lasers (XFELs), nuclear magnetic resonance (NMR), cryo-electron microscopy (cryo-EM), Micro-electron diffraction (Micro-ED), and small-angle X-ray scattering (SAXS), and their potential applications to M-T7 structural biology.
000472123 536__ $$0G:(DE-HGF)POF4-6G3$$a6G3 - PETRA III (DESY) (POF4-6G3)$$cPOF4-6G3$$fPOF IV$$x0
000472123 588__ $$aDataset connected to CrossRef Book Series, Journals: bib-pubdb1.desy.de
000472123 693__ $$0EXP:(DE-H253)P-P12-20150101$$1EXP:(DE-H253)PETRAIII-20150101$$6EXP:(DE-H253)P-P12-20150101$$aPETRA III$$fPETRA Beamline P12$$x0
000472123 7001_ $$0P:(DE-H253)PIP1084662$$aGisriel, Christopher$$b1
000472123 7001_ $$0P:(DE-H253)PIP1023170$$aFromme, Petra$$b2
000472123 7001_ $$0P:(DE-HGF)0$$aMartin-Garcia, Jose M.$$b3$$eCorresponding author
000472123 773__ $$a10.1007/978-1-0716-1012-1_8
000472123 8564_ $$uhttps://link.springer.com/protocol/10.1007%2F978-1-0716-1012-1_8
000472123 8564_ $$uhttps://bib-pubdb1.desy.de/record/472123/files/Viruses%20as%20Therapeutics.pdf$$yRestricted
000472123 8564_ $$uhttps://bib-pubdb1.desy.de/record/472123/files/Viruses%20as%20Therapeutics.pdf?subformat=pdfa$$xpdfa$$yRestricted
000472123 909CO $$ooai:bib-pubdb1.desy.de:472123$$pVDB
000472123 9101_ $$0I:(DE-HGF)0$$6P:(DE-H253)PIP1084662$$aExternal Institute$$b1$$kExtern
000472123 9101_ $$0I:(DE-588)1043621512$$6P:(DE-H253)PIP1084662$$aEuropean XFEL$$b1$$kXFEL.EU
000472123 9101_ $$0I:(DE-H253)_CFEL-20120731$$6P:(DE-H253)PIP1023170$$aCentre for Free-Electron Laser Science$$b2$$kCFEL
000472123 9101_ $$0I:(DE-HGF)0$$6P:(DE-H253)PIP1023170$$aExternal Institute$$b2$$kExtern
000472123 9131_ $$0G:(DE-HGF)POF4-6G3$$1G:(DE-HGF)POF4-6G0$$2G:(DE-HGF)POF4-600$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bForschungsbereich Materie$$lGroßgeräte: Materie$$vPETRA III (DESY)$$x0
000472123 9141_ $$y2021
000472123 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-11
000472123 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-11
000472123 9201_ $$0I:(DE-H253)EMBL-User-20120814$$kEMBL-User$$lEMBL-User$$x0
000472123 980__ $$abook
000472123 980__ $$aVDB
000472123 980__ $$aI:(DE-H253)EMBL-User-20120814
000472123 980__ $$aUNRESTRICTED